

**THE UNIVERSITY OF MANCHESTER**  
**ANIMAL WELFARE AND ETHICAL REVIEW BODY**

Thursday, 28<sup>th</sup> September 2017

*Present:*

[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

*By invitation:*

[REDACTED]

*Apologies:*

[REDACTED]

*In attendance:*

[REDACTED]

Before the commencement of business the Chair welcomed [REDACTED], who was attending his first meeting

**1. Minutes**

*Confirmed:* The minutes of the meeting held on 11<sup>th</sup> July 2017,

**2. Matters arising**

**2.1 [REDACTED]: Neural basis of tactile behaviour**

*Reported:* That the Chairman had confirmed that there was consistency between the Home Office licence application and the AWERB1 form and that the revisions requested by AWERB had been satisfactorily completed and the project approved.

**2.2. North West Regional AWERB Hub**

*Reported:* That the next hub meeting would take place on 15<sup>th</sup> November at the Alderley Park site. A Newsletter had been circulated.

**2.3 Retrospective review**

*Reported:* That the BSF was developing a form for retrospective review. This would commence with the review of projects which included a severe protocol

**4. Report from the NC3Rs Regional Programme Manager**

The NC3Rs Regional Programme Manager reported that:



██████████

*To Generate an mCherry-Labelled Podocyte Mouse Model*

(c) ██████████, *Creation, breeding and maintenance of genetically altered rodents:*

None

(d) Applications for secondary availability for imaging purposes

██████████

*Investigation of Anti-Vascular Treatments for Ovarian Cancer (██████████) (Primary at CRUK MI)*

(d) That for Personal Licences there were 17 new licences, 7 amendments, 11 surrendered and 0 renewed.

## 7. Application for new Research Project Licence

7.1 ██████████, *Maternal Fasting & Offspring Health*

*Considered:* A completed AWERB1 form, with written comments by the NVS, NACWO and NTCO, and NTS.

*Interviewed:* ██████████

*Noted:*

- (1) That this was a development and continuation of an current licence.
- (2) Although there was no peer review, there was a letter of support from ██████████
- (3) There was likely to be stable funding via studentships
- (4) There would be a limited number of cognitive tests for any one animal
- (5) Greater clarity was suggested in Replacement section of the NTS.

*Resolved:* To recommend approval, subject to re-drafting the Replacement section of the NTS.

7.2 ██████████, *Immunogenicity of biologics*

*Considered:* A completed AWERB1 form, with written comments by the NVS, NACWO and NTCO, and NTS.

*Interviewed:* ██████████

*Noted:*

- (1) That this was a continuation of two licences
- (2) That "cytokine storm" on page 4 needed an explanation
- (3) The Refinement section of the NTS needed to be more succinct

*Resolved:* To recommend approval, subject to an explanation of cytokine storm and a re-draft of the Refinement section of the NTS.

7.3 ██████████, *Treatment and Pathology of Neurological Diseases*

*Considered:* A completed AWERB1 form, with written comments by the NVS, NACWO and NTCO, and NTS.

*Interviewed:* ██████████

*Noted:*

- (1) This developed and replaced a current 5 year licence
- (2) AWERB members agreed that your AWERB1 form fulfilled the purposes of the review but found it a hard read. For clarity AWERB and the HO recommend that several smaller, discrete project licences and usually preferable to large and complex licences that attempt to embrace too many areas of experimentation. This is not a requirement for the present application, but something to consider for subsequent applications.
- (3) It was explained that at 15% weight loss concerns would be raised and closer monitoring introduced; 20% weight loss would be an end point
- (4) The end points on page 7 would be modified for greater clarity.
- (5) Numbers appeared not to tie in with Home office licence.

*Resolved:* To recommend approval, subject to the above clarifications and transferring the NTS to the new Home Office format.

7.4 ██████████, *Determining important regulatory pathways that control immune responses to infection*

*Considered:* A completed AWERB1 form, with written comments by the NVS, NACWO and NTCO, and NTS.

*Interviewed:* ██████████

*Noted:* The committee discussed, at some length, end points and the procedures you would have in place to monitor animals that might reach the severe level. The decision of the meeting was to recommend the approval of your project. However, the committee were interested in the frequency of progression to a severe banding in the current project, and would welcome sight of that information when available. In addition, it would be a good idea to provide in the present application, on the basis of experience to date, an estimate of the number of mice that would be expected to progress to a severe banding.

*Resolved:* To recommend approval, and to ask for the return, in due course, of an amended version of the AWERB1 form, highlighting any changes made.

**8. Retirement of ██████████**

This was the last meeting before ██████████ retired as NVS. The Chairman and AWERB members paid tribute to the significant contribution he had made to the formulation and development of the Local Ethical Review Process and subsequently AWERB, and more generally to animal welfare issues in the scientific use of animals in the University. He was greatly thanked for his wise guidance to AWERB members who wished him well in his retirement.

